先声药业：FDA approved trilaciclib for chemotherapy-induced myelosuppression

原标题：先声药业：FDA approved trilaciclib for chemotherapy-induced myelosuppression 来源：同花顺金融研究中心

招银证券3月1日发布对先声药业的研报，摘要如下：

Maintain BUY. We expect Simcere’s attributable net profit to grow from RMB1,004mn in 2019 to RMB1,453mn in 2022E, representing a CAGR of 13.1%. We maintain our target price of HK$13.84 based on a 10-year DCF valuation (WACC: 10.4%, terminal growth rate: 2.0%). Risks: Lower-than-expected sales from key products, slower-than-expected RD progress of innovative drugs.